DISCOVERY SESSION – EXHIBITING COMPANIES
Acadia Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Its products include ACP-103, which is in Phase III clinical trials for the treatment of Parkinson’s disease psychosis, and in Phase II clinical trials for the treatment of schizophrenia and sleep maintenance insomnia. The company also has collaboration with Sepracor, Inc. for the discovery and development of small molecule drug candidates. Acadia Pharmaceuticals, formerly known as Receptor Technologies, Inc., is headquartered in San Diego, California.
For further information, please visit www.acadia-pharm.com.
Airsonett is a research based medical technology company. Its unique technology leads the development of prophylactic treatment of allergic asthma (Protexo) and infection control in operation theatres (Opragon). Airsonett has an extensive portfolio of patents and is investing in clinical research and product development which has resulted in innovative MedTech products that competes with traditional pharmaceutical treatment for asthma. The Temperature controlled Laminar Airflow (TLA) technique is developed from the industrial clean room technology. Airsonett has been awarded the title MedTech Company of the Year 2009 in Sweden. The company is now working towards an international expansion.
For further information, please visit www.airsonett.com.
Doxa, a Swedish-based medical device company, develops and markets bioceramic dental products. Ceramir® Crown & Bridge, the first product, was launched in Sweden in November 2009. Ceramir Crown & Bridge is an advanced dental cement used for permanent fixture of dental crowns and bridges. Ceramir® Crown & Bridge has been awarded the 2010 Frost & Sullivan European Prize for “New Product Innovation of the Year”. The first of its kind, this product heralds the introduction of an entirely new class of nanotechnology-based dental materials.
For further information, please visit www.doxa.se.
Forecast Diagnostics is a Swedish diagnostics company currently being founded by members of the senior management team of Åmic AB that was acquired by Johnson & Johnson (J&J) in 2008. The team has purchased a license option from J&J for the Forecast Technology, which enables laboratory class blood tests in a rapid Point-of-Care (POC) format – No other POC system can offer this class of performance directly in the Emergency Room or Doctors Office. The team is seeking capital to purchase the full license and infrastructure, re-establish laboratory and manufacturing facilities and conduct business development activities to secure commercial partnerships for products based on Forecast Technology.
IMED is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. IMED´s first product, F45D9 is in late preclinical phase and IMED is currently preparing for First in Human (FIH) clinical studies.
For further information, please visit www.imed.se.
IntelliMedicine Systems is a US based Converging Technologies company. IntelliMedicine Systems is leveraging exponential technologies to develop an integrated platform that enables evidence based, patient specific, personalized medicine. The IntelliMedicine system individualizes and optimizes therapy, and will lead to more convenience, higher compliance, decreased side effects, lower costs and improved patient outcomes.
Likvor, a medical device company based in Umeå, north of Sweden, has developed an instrument to be used in neurological investigations. The LIKVOR CELDA® Instrument is the result of over 30 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. Likvor is marketing the LIKVOR CELDA® Instrument and LIKVOR CELDA® TOOLS. Likvor continues to develop new methods and devices in the area of CSF dynamics, together with the researchers at Umeå University and Umeå University Hospital.
For further information, please visit www.likvor.com.